Actively Recruiting
CfDNA in Hereditary And High-risk Malignancies 2
Led by University Health Network, Toronto · Updated on 2025-12-16
1000
Participants Needed
8
Research Sites
397 weeks
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
B
British Columbia Cancer Agency
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes. If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. The study will compare cancer detection rates between those receiving the new blood test and those receiving standard care, assess if the test leads to earlier cancer diagnosis, and evaluate its impact on patient outcomes. The study will also use questionnaires and interviews to understand how patients feel about the blood test, its incorporation into routine medical care, and perceptions of the medical value of test results. This research could lead to more effective and less invasive cancer screening for high-risk individuals.
CONDITIONS
Official Title
CfDNA in Hereditary And High-risk Malignancies 2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a confirmed diagnosis of hereditary breast and ovarian cancer, Lynch Syndrome, Neurofibromatosis type I, Li-Fraumeni Syndrome, PALB2, or Hereditary Diffuse Gastric Cancer, including those with pathogenic variants or suggestive family history
- Patients receiving standard-of-care clinical cancer assessment under a provincial screening or surveillance program
- Patients who have signed and dated informed consent for this study
You will not qualify if you...
- Patients with cancer diagnosed and treated within 3 years before first study sample collection
- Patients diagnosed with cancer more than 3 years before first study sample collection who have never been treated
- Patients currently undergoing investigations for suspected cancer
- Patients unable to comply with tri-annual blood sample collection if assigned to the experimental group
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
BC Cancer Agency
Vancouver, British Columbia, Canada, V5Z 4E6
Not Yet Recruiting
2
Eastern Health
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Not Yet Recruiting
3
IWK Health Centre
Halifax, Nova Scotia, Canada, B3K 6R8
Not Yet Recruiting
4
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1E8
Not Yet Recruiting
5
Sinai Health System
Toronto, Ontario, Canada, M5G 1X5
Actively Recruiting
6
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
7
Women's College Hospital
Toronto, Ontario, Canada, M5S 1B2
Not Yet Recruiting
8
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Not Yet Recruiting
Research Team
J
Julia Sobotka, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here